Inventor · disambiguated record
Ambarish Shah
Also filed as: SHAH AMBARISH · SHAH AMBARISH UMAKANT
6 granted patents·15 pending applications·43 citations·filing 2008–2025
80Inventor score
Top patents by PatentIndex Score
21 records- 0191US9308257B2Protein formulationSHARMA SR MONIKA S·Filed 2008·Granted Apr 12, 2016·27 cites·22 claims
- 0286US2025333493A1Formulations of monoclonal antibodiesMEDIMMUNE LTD·Filed 2024·Application pending·0 cites
- 0384US10072083B2Method for purifying active polypeptides or immunoconjugatesMEDIMMUNE LLC·Filed 2017·Granted Sep 11, 2018·4 cites·21 claims
- 0484US2025163142A1Formulations of monoclonal antibodiesMEDIMMUNE LTD·Filed 2024·Application pending·0 cites
- 0583US9580461B2Method for purifying active polypeptides or immunoconjugatesLINKE THOMAS·Filed 2011·Granted Feb 28, 2017·11 cites·16 claims
- 0675US2021395370A1Method for purifying active polypeptides or immunoconjugatesMEDIMMUNE LTD·Filed 2021·Application pending·0 cites
- 0774US2022204597A1Formulations of monoclonal antibodiesMEDIMMUNE LTD·Filed 2021·Application pending·0 cites
- 0871US2022089713A1Formulations of monoclonal antibodiesMEDIMMUNE LTD·Filed 2021·Application pending·0 cites
- 0970US11136396B2Method for purifying active polypeptides or immunoconjugatesMEDIMMUNE LTD·Filed 2020·Granted Oct 5, 2021·0 cites·19 claims
- 1065US10556955B2Method for purifying active polypeptides or immunoconjugatesMEDIMMUNE LTD·Filed 2018·Granted Feb 11, 2020·0 cites·10 claims
- 1164US10421811B2Compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodiesMEDIMMUNE LLC·Filed 2017·Granted Sep 24, 2019·1 cites·19 claims
- 1263US2020283516A1Formulations of monoclonal antibodiesMEDIMMUNE LTD·Filed 2018·Application pending·0 cites
- 1362US2020216541A1Antibody formulationMEDIMMUNE LLC·Filed 2019·Application pending·0 cites
- 1459US2011293605A1Antibody formulationSATHISH HASIGE·Filed 2009·Application pending·0 cites
- 1554US2025319167A1Intravenous compositions of tissue kallikrein-1 and related methodsDIAMEDICA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1650US2018243415A1Liquid antibody formulation with improved aggregation propertiesMEDIMMUNE LTD·Filed 2018·Application pending·0 cites
- 1749US2015344557A1Liquid Antibody Formulation With Improved Aggregation PropertiesMEDIMMUNE LLC·Filed 2013·Application pending·0 cites
- 1849US2019382494A1Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodiesMEDIMMUNE LLC·Filed 2019·Application pending·0 cites
- 1948US2017174766A1Antibody formulationMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 2047US2016215051A1Protein formulationMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 2132US2012148576A1Humanized anti-cd 19 antibody formulationsSHARMA MONIKA S·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →